Gaomei Genetics, a early cancer detection biotechnology company, has recently closed its Pre-A round, raising tens of millions of yuan.
This is the first financing for Gaomei after the successful merger of Zhejiang Gomics and Known Biotech. WinX Capital continued to serve as the sole financial advisor.
Lu Guohua, CEO of Gaomei claims that the proceeds will be primarily used to accelerate the launch of the liver cancer early detection product and the registration filing of the liver cancer early screening IVD product.
In the meantime, further expand the company’s leading advantages in the multi-cancer early detection database, which already covers the top 10 common cancers in the Chinese population, and continue to promote research and development of technologies for early detection of gastrointestinal and gynecological tumors.
Located in Nanjing, Gaomei Genetics is a high-tech enterprise focusing on tumor epigenetics and large-scale data analysis, covering early cancer screening, accompanying diagnosis, dynamic monitoring, prognosis assessment, among others.